Zemskov outlined possible areas of cooperation with Uzbekistan

Promomed 26 April 2022

Speaking about the capabilities of the Biokhimik plant (part of Promomed Group) at the round table «Partnership between Russia and Uzbekistan in the pharmaceutical and medical industry», Dmitry Zemskov, Executive Director of Biokhimik JSC, noted the innovative nature of the company's drug portfolio and the rapid growth of its production capacity, which opens up prospects for cooperation.

«We can offer the supply of our innovative drugs for the healthcare system of Uzbekistan. We see that the market is growing, however the main growth driver is the generic component. We are ready to supply original innovative drug products at reasonable prices so that Uzbekistan's healthcare has the most effective medicines and technologies,» said the Executive Director of Biokhimik JSC Dmitry Zemskov.

Dmitry Zemskovbelieves that the localization of original drugs in cooperation with partners in Uzbekistan is yet another opportunity to provide patients in this country with modern means of therapy.

The speaker also spoke about the Promomed Group's substance program: «This year we are completing construction of a large plant for the production of various substances with a capacity of up to 400 tons per year, including anti-cancer and antiviral substances. We expect to satisfy not only the needs of our own production, but are also ready to discuss various forms of partnership.»

Dmitry Zemskovalso reminded the participants about correction of business alliances that is currently underway. This is a great time for Uzbek manufacturers of corresponding nomenclature, for example, workwear, to offer their products. The company is open to new partnerships in many areas.